Singular Genomics Systems is a life science technology company that is utilizing next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians. Co. has developed a proprietary NGS technology, which it refers to as its Sequencing Engine. Co.'s primary product, the G4, targets the NGS market and is comprised of an instrument and associated menu of consumable kits. Co.'s second product in development, the PX, combines single-cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to provide a versatile multiomics solution. We show 12 historical shares outstanding datapoints in our coverage of OMIC's shares outstanding history.
Understanding the changing numbers of OMIC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like OMIC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching OMIC by allowing them to research OMIC shares outstanding history
as well as any other stock in our coverage universe. |
Free OMIC Email Alerts:
Video: Shares Outstanding Importance
